secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2026-01-28T23:59:59+00:00
Accession:  0001140361-26-002608
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech: NCI-led Phase 2 study of PDS01ADC shows median PFS 9.6 months in mCRPC
--------------------------------------------------------------------------------

- Median PFS of 9.6 months (range 4.3-32.2) for PDS01ADC plus docetaxel in 3rd-line mCRPC patients.
- Median PSA decline of 40%; 6 of 16 patients achieved >50% PSA decline.
- Data presented at AACR special conference on prostate cancer (Boston, Jan 20-22, 2026).
- Study by NCI/NIH evaluating PDS01ADC synergy with docetaxel in advanced prostate cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126002608/0001140361-26-002608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126002608/ef20064069_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-002608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer